ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide.
| Revenue (Most Recent Fiscal Year) | $8.28B |
| Net Income (Most Recent Fiscal Year) | $791.47M |
| PE Ratio (Current Year Earnings Estimate) | 13.11 |
| PE Ratio (Trailing 12 Months) | 12.93 |
| PEG Ratio (Long Term Growth Estimate) | 2.25 |
| Price to Sales Ratio (Trailing 12 Months) | 1.66 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.41 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 8.30 |
| Pre-Tax Margin (Trailing 12 Months) | 10.11% |
| Net Margin (Trailing 12 Months) | 9.82% |
| Return on Equity (Trailing 12 Months) | 10.95% |
| Return on Assets (Trailing 12 Months) | 6.23% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.29 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.29 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.35 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $117.92 |
| Earnings per Share (Most Recent Fiscal Quarter) | $3.16 |
| Earnings per Share (Most Recent Fiscal Year) | $13.61 |
| Diluted Earnings per Share (Trailing 12 Months) | $9.72 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 80.76M |
| Free Float | 45.22M |
| Market Capitalization | $13.44B |
| Average Volume (Last 20 Days) | 1.79M |
| Beta (Past 60 Months) | 1.17 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 44.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 95.61% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |